Lead Product(s): Patiromer
Therapeutic Area: Nephrology Product Name: Veltassa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.